Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency
摘要:
Optimization of kinase selectivity for a set of benzothiophene MK2 inhibitors provided analogs with potencies of less than 500 nM in a cell based assay. The selectivity of the inhibitors can be rationalized by examination of X-ray crystal structures of inhibitors bound to MK2.
Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency
摘要:
Optimization of kinase selectivity for a set of benzothiophene MK2 inhibitors provided analogs with potencies of less than 500 nM in a cell based assay. The selectivity of the inhibitors can be rationalized by examination of X-ray crystal structures of inhibitors bound to MK2.
MK2 inhibitors, synthesis thereof, and intermediates thereto
申请人:Celgene CAR LLC
公开号:US10894796B2
公开(公告)日:2021-01-19
The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
本发明提供了制备 MK2 抑制剂及其相关中间体的方法。
MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
申请人:Celgene CAR LLC
公开号:US20210139501A1
公开(公告)日:2021-05-13
The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency
作者:David R. Anderson、Marvin J. Meyers、Ravi G. Kurumbail、Nicole Caspers、Gennadiy I. Poda、Scott A. Long、Betsy S. Pierce、Matthew W. Mahoney、Robert J. Mourey、Mihir D. Parikh
DOI:10.1016/j.bmcl.2009.02.017
日期:2009.8
Optimization of kinase selectivity for a set of benzothiophene MK2 inhibitors provided analogs with potencies of less than 500 nM in a cell based assay. The selectivity of the inhibitors can be rationalized by examination of X-ray crystal structures of inhibitors bound to MK2.